Form 8-K - Current report:
SEC Accession No. 0001213900-25-061639
Filing Date
2025-07-07
Accepted
2025-07-07 08:43:26
Documents
13
Period of Report
2025-06-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0248238-8k_allarity.htm   iXBRL 8-K 34962
2 EMPLOYMENT AGREEMENT, DATED AS OF JULY 1, 2025, BY AND BETWEEN ALLARITY THERAPEU ea024823801ex10-1_allarity.htm EX-10.1 129865
  Complete submission text file 0001213900-25-061639.txt   363661

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE allr-20250630.xsd EX-101.SCH 3014
4 XBRL LABEL FILE allr-20250630_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE allr-20250630_pre.xml EX-101.PRE 22358
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0248238-8k_allarity_htm.xml XML 3685
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 251107063
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)